Translation of "Significant disease" in German

Patients with clinically significant uncontrolled cardiovascular disease were excluded from clinical studies.

Patients with uncontrolled or significant cardiovascular disease were not included in the clinical studies.

In all phase 3 studies, patients were excluded for “significant hepatic disease”.

Oster and Ross recognized BMXO as a long-term biologically significant source of disease.

The benefits of garlic and olive leaf are beings with a significant cardiovascular disease.

In addition, patients with clinically significant uncontrolled cardiovascular disease were excluded from clinical studies.

At its meeting on 6 September 2005, the working group on avian influenza of the Standing Committee on the Food Chain and Animal Health recommended, inter alia, that the occurrence of abnormal mortality and significant disease outbreaks in wild birds should be subjected to surveillance and to laboratory tests for avian influenza.

Member States shall ensure that the competent authorities make appropriate arrangements with wild bird, hunting and other relevant organisations which shall notify without delay to the competent authorities any abnormal mortality or significant disease outbreaks occurring in wild birds and in particular wild water birds.

It should also be used with caution in patients who suffer from pre-existing cardiac disorders, Patients with pre-existing significant cardiac disease, such as congestive heart failure, coronary artery disease or arrhythmia, should be monitored for worsening of their cardiac condition, particularly during initiation of treatment with Betaferon.

During the post-marketing period very rare reports have been received of worsening of cardiac status in patients with pre-existing significant cardiac disease temporarily associated with the initiation of Extavia therapy.

Miglustat has not been evaluated in patients with a history of significant gastrointestinal disease, including inflammatory bowel disease.

Patients with known brain metastasis, uncontrolled hypertension, significant heart disease, or NYHA Class IIIV heart failure were excluded.

The PRAC recommended that hydroxyzine should be contra-indicated in patients with a known acquired or congenital QT interval prolongation as well as in patients with a known risk factor to QT interval prolongation including a known cardiovascular disease, significant electrolytes imbalance (hypokalaemia, hypomagnesaemia), family history of sudden cardiac death, significant bradycardia, concomitant use with other drugs known to prolong the QT interval and/or induce Torsades de Pointes.

In clinical studies, patients with uncontrolled or significant cardiac disease (e.g., recent myocardial infarction, congestive heart failure or unstable angina) were excluded.

In clinical studies, patients with uncontrolled or significant cardiac disease (e.g., recent myocardial infarction, congestive heart failure, unstable angina or clinically significant bradycardia) were excluded.

During the post-marketing period very rare reports have been received of worsening of cardiac status in patients with pre-existing significant cardiac disease temporarily associated with the initiation of Betaferon therapy.

As the benefit observed in patient with 4+ nodes was not statistically significant on disease-free survival (DFS) and overall survival (OS), the positive benefit/risk ratio for TAC in patients with 4+ nodes was not fully demontrated at the final analysis (see section 5.1).

Caution should be exercised in patients with clinically significant pulmonary disease, including diffuse interstitial pulmonary fibrosis and severe chronic obstructive pulmonary disease, as no studies have been performed in these patients.

While Betaferon does not have any known direct-acting cardiac toxicity, symptoms of the flu-like syndrome associated with beta interferons may prove stressful to patients with pre-existing significant cardiac disease.

For composite endpoints, statistically significant efficacy against disease was demonstrated against HPV types phylogenetically related to HPV 16 (primarily HPV 31) whereas no statistically significant efficacy was observed for HPV types phylogenetically related to HPV 18 (including HPV 45).

Rebif should be initiated with caution in patients with a history of significant liver disease, clinical evidence of active liver disease, alcohol abuse or increased serum ALT (> 2.5 times ULN).

Patients who switched to Arimidex after 2 years of adjuvant treatment with tamoxifen had a significant improvement in disease free survival compared to patients who remained on tamoxifen.